Sinovac’s COVID-19 vaccine candidate induced an immune response, according to preliminary data from its phase 1/2 trial.

The Chinese drugmaker said the phase 2 portion of the trial showed the vaccine, called CoronaVac, induced neutralizing antibodies in 90 percent of participants 14 days after vaccination.

Sinovac said it will advance the vaccine to a phase 3 study “in the near future.”